Drugs / Cedirogant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05376839 | Jul → Nov 2022 | — | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03922607 | Jun 2019 → Apr 2021 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05044234 | Nov 2021 → Nov 2022 | psoriasis | AbbVie | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cedirogant | “Cedirogant (ABBV-157) is an orally bioavailable inverse agonist of retinoic acid-related orphan receptor gamma thymus.” PMID 38231873 ↗ Jan 2024 |
| Known as | ABBV-157 | “Cedirogant (ABBV-157) is an orally bioavailable inverse agonist of retinoic acid-related orphan receptor gamma thymus.” PMID 38231873 ↗ Jan 20241“Multiple Doses of Cedirogant (ABBV-157) in Subjects” NCT05376839 ↗ |
| Known as | ABV-157 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095174 ↗ |
| Modality | Small molecule | — CHEMBL5095174 ↗ |
| Route | Oral | “ABBV-157 will be administered orally as capsule” NCT03922607 ↗ |
| Target | RORC | “Cedirogant (ABBV-157) is an orally bioavailable inverse agonist of retinoic acid-related orphan receptor gamma thymus.” PMID 38231873 ↗ Jan 2024 |